--- title: "ALV-100 | PepTracker Pro" url: https://peptrackerpro.com/peptides/alv-100 description: "A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # ALV-100 Low Evidence A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance. Aliases Alveus ALV-100 +1 more Evidence Low Evidence Last Updated 2026-05-31 Reading Time 3 min ## What It Is ALV-100 is a bifunctional peptide that combines glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor (GLP-1R) agonism in a single molecule. It is the lead candidate of Alveus Therapeutics, a Philadelphia-based obesity and metabolic-disease company (with research operations in Copenhagen, Denmark) that emerged from stealth on January 8, 2026 with a $159.8 million Series A led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds; the round was later upsized to roughly $197 million in a second and final close in February 2026. The molecule pairs GLP-1 receptor agonism, which drives appetite suppression and weight loss, with GIPR antagonism, a genetically validated pathway that the company links to improved quality of weight loss (preserving lean mass relative to fat) and more durable long-term maintenance. Mechanistically it sits in the same GIPR-antagonist + GLP-1 design space as Amgen's MariTide (maridebart cafraglutide). On January 23, 2026, Alveus announced FDA clearance of its Investigational New Drug (IND) application and dosing of the first patient in a Phase 1b trial of ALV-100 for obesity. Alveus is also advancing a differentiated amylin pipeline, including ALV-200, a highly selective amylin receptor 3 (AMYR3) peptide agonist expected to enter first-in-human studies within roughly 18 months. ALV-100 is one of the most heavily financed new obesity peptides to enter the clinic in early 2026 and reflects the field's shift toward combination and lean-mass-sparing mechanisms. Also known as: Alveus ALV-100, ALV100 ## Regulatory Status Investigational FDA cleared the IND and the first patient was dosed in a Phase 1b obesity trial in January 2026. Not approved in any jurisdiction. Effective: 2026 View FDA Source (https://www.globenewswire.com/news-release/2026/01/23/3224643/0/en/Alveus-Therapeutics-Announces-FDA-Clearance-of-IND-and-First-Patient-Dosed-in-Phase-1b-Trial-of-ALV-100-for-Obesity.html) ## Why Researchers Study It ALV-100 represents the GIPR-antagonist plus GLP-1-agonist combination class — the same broad mechanism as Amgen's MariTide — that aims to deliver durable weight loss with better preservation of lean mass and stronger weight maintenance after the active phase. Researchers study it because layering GIPR antagonism onto GLP-1 agonism may improve the quality and durability of weight loss beyond what single-mechanism GLP-1 drugs achieve, and because the asset is well financed and already in the clinic. ## Proposed Mechanisms - Agonizes the GLP-1 receptor to suppress appetite and reduce body weight - Antagonizes (blocks) the GIP receptor, a pathway linked to the quality and durability of weight loss - Bifunctional single-molecule design intended to preserve lean mass relative to fat loss - Aims to improve long-term weight maintenance after the active weight-loss phase ## Evidence Snapshot Low Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Company / financing | Alveus Therapeutics emergence from stealth with Series A financing | Launched Jan 8, 2026 with $159.8M Series A (upsized to ~$197M in Feb 2026) to advance ALV-100 and an amylin pipeline | Source: https://www.globenewswire.com/news-release/2026/01/08/3215272/0/en/Alveus-Therapeutics-Launches-with-160-Million-Series-A-Financing-to-Advance-Next-Generation-Therapies-for-Obesity-and-Metabolic-Diseases.html | | Human (Phase 1b, ongoing) | First-in-human Phase 1b obesity trial | FDA cleared the IND and first patient dosed in late January 2026; clinical efficacy data not yet reported | Source: https://www.globenewswire.com/news-release/2026/01/23/3224643/0/en/Alveus-Therapeutics-Announces-FDA-Clearance-of-IND-and-First-Patient-Dosed-in-Phase-1b-Trial-of-ALV-100-for-Obesity.html | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation Researching ALV-100? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=alv-100) ## Safety & Cautions - Only early clinical-stage (Phase 1b) status; no human efficacy data reported yet - Human weight-loss magnitude and lean-mass benefit not established - Long-term safety and efficacy unknown - Available only through clinical trial enrollment - Not FDA-approved; not a compounding-eligible peptide ## Comparisons See how ALV-100 compares to related peptides: ALV-100 vs ALV-200: https://peptrackerpro.com/compare/alv-100-vs-alv-200 ALV-100 vs AT7687: https://peptrackerpro.com/compare/alv-100-vs-at7687 ALV-100 vs Cagrilintide: https://peptrackerpro.com/compare/alv-100-vs-cagrilintide ALV-100 vs Maridebart Cafraglutide (MariTide): https://peptrackerpro.com/compare/alv-100-vs-maridebart-cafraglutide ALV-100 vs Tirzepatide: https://peptrackerpro.com/compare/alv-100-vs-tirzepatide ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Alveus Therapeutics Launches with $160 Million Series A Financing (Jan 8, 2026) PubMed (https://www.globenewswire.com/news-release/2026/01/08/3215272/0/en/Alveus-Therapeutics-Launches-with-160-Million-Series-A-Financing-to-Advance-Next-Generation-Therapies-for-Obesity-and-Metabolic-Diseases.html) 2. [2] Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 (Jan 23, 2026) PubMed (https://www.globenewswire.com/news-release/2026/01/23/3224643/0/en/Alveus-Therapeutics-Announces-FDA-Clearance-of-IND-and-First-Patient-Dosed-in-Phase-1b-Trial-of-ALV-100-for-Obesity.html) 3. [3] BioPharma Dive — Alveus launches with $160M to advance MariTide-like obesity drug PubMed (https://www.biopharmadive.com/news/alveus-obesity-biotech-startup-glp-gipr-amylin-financing/809148/) ### Keep researching in the app - Log ALV-100 to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=alv-100 Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### ALV-200 Low Evidence ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing. View Details: https://peptrackerpro.com/peptides/alv-200 \+ Compare: https://peptrackerpro.com/compare?select=alv-200 Track in App: https://app.peptrackerpro.com/?add=alv-200 ### AT7687 Low Evidence A first-in-class GIPR antagonist peptide in early clinical development for obesity, designed as a once-weekly combination partner that adds weight loss and improves insulin sensitivity independent of appetite suppression. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control View Details: https://peptrackerpro.com/peptides/at7687 \+ Compare: https://peptrackerpro.com/compare?select=at7687 Track in App: https://app.peptrackerpro.com/?add=at7687 ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/maridebart-cafraglutide \+ Compare: https://peptrackerpro.com/compare?select=maridebart-cafraglutide Track in App: https://app.peptrackerpro.com/?add=maridebart-cafraglutide ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "ALV-100", "description": "A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance.", "url": "https://peptrackerpro.com/peptides/alv-100", "lastReviewed": "2026-05-31", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "ALV-100", "item": "https://peptrackerpro.com/peptides/alv-100" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following next-generation obesity mechanisms beyond single GLP-1 agonists?", "acceptedAnswer": { "@type": "Answer", "text": "ALV-100 is a research peptide studied in preclinical models. A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance." } }, { "@type": "Question", "name": "Those interested in GIPR antagonism combined with GLP-1 agonism (MariTide-like designs)?", "acceptedAnswer": { "@type": "Answer", "text": "ALV-100 is a research peptide studied in preclinical models. A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance." } }, { "@type": "Question", "name": "Individuals tracking lean-mass preservation and quality-of-weight-loss strategies?", "acceptedAnswer": { "@type": "Answer", "text": "ALV-100 is a research peptide studied in preclinical models. A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance." } }, { "@type": "Question", "name": "Healthcare providers monitoring well-financed early-stage obesity pipeline assets?", "acceptedAnswer": { "@type": "Answer", "text": "ALV-100 is a research peptide studied in preclinical models. A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance." } } ] } ] ```